Compare Amgen, Inc. (AMGN) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.88. The key difference: Amgen, Inc. pays a 2.77% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | RDTE | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $388.16 | $34.72 |
52-Week Low | $271.18 | $26.40 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RDTE trades at $28.9, down 0.34% today, with technical indicators signaling a bearish trend. The stock exhibits frequent dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights structural risks to capital preservation.
Outlook remains cautious due to technical weakness and media concerns over capital erosion. Investment opportunity is limited without fundamental data; risks include downside exposure and capped upside potential from the ETF's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
